Skip to main content
Research
  1. Queen Mary University of London
  2. Research
  3. Publications

Publications: Dr Matejka Rebolj

Back to Search
Rebolj M, Brentnall A, Cuschieri K ( 2024 ) . PREDICTABLE CHANGES IN THE ACCURACY OF HUMAN PAPILLOMAVIRUS TESTS AFTER VACCINATION: REVIEW WITH IMPLICATIONS FOR PERFORMANCE MONITORING IN CERVICAL SCREENING . British Journal of Cancer
Brentnall AR, Cuschieri K, Sargent A, Berkhof J, Rebolj M ( 2023 ) . Staged design recommendations for validating relative sensitivity of self-sample human papillomavirus tests for cervical screening . Journal of Clinical Epidemiology vol. 166 ,
Rebolj M, Sargent A, Njor SH, Cuschieri K ( 2022 ) . Widening the offer of human papillomavirus self‐sampling to all women eligible for cervical screening: Make haste slowly . International Journal of Cancer vol. 153 , ( 1 ) 8 - 19 .
Dernovsek MZ, Rupel VP, Rebolj M, Tavcar R ( 2020 ) . Quality of life and treatment costs in schizophrenic outpatients, treated with depot neuroleptics . European Psychiatry vol. 16 , ( 8 ) 474 - 482 .
Njor SH, Paci E, REBOLJ M ( 2018 ) . As you like it: How the same data can support manifold views of overdiagnosis in breast cancer screening . International Journal of Cancer
de Thurah L, Bonde J, Lam JUH, Rebolj M ( 2017 ) . Not all HPV nucleic acid tests are equal: only those calibrated to detect high grade lesions matter for cervical screening: Response to ‘Concordant testing results between various human papillomavirus assays in primary cervical cancer screening: systematic review’ by de Thurah, Bonde, Uyen, Lam and Rebolj. Published 27 May, 2017 . Clinical Microbiology and Infection vol. 24 , ( 4 ) 438 - 439 .
Lam JUH, Elfström KM, Ejegod DM, Pedersen H, Rygaard C, Rebolj M, Lynge E, Juul KE et al. ( 2017 ) . High-grade cervical intraepithelial neoplasia in human papillomavirus self-sampling of screening non-attenders . British Journal of Cancer vol. 118 , ( 1 ) 138 - 144 .
Rebolj M, Njor S, Lynge E, Preisler S, Ejegod D, Rygaard C, Bonde J ( 2017 ) . Referral population studies underestimate differences between human papillomavirus assays in primary cervical screening . Cytopathology vol. 28 , ( 5 ) 419 - 428 .
Lam JUH, Rebolj M, Ejegod DM, Pedersen H, Rygaard C, Lynge E, Harder E, Thomsen LT et al. ( 2017 ) . Prevalence of Human Papillomavirus in Self-Taken Samples from Screening Nonattenders . Journal of Clinical Microbiology vol. 55 , ( 10 ) 2913 - 2923 .
de Thurah L, Bonde J, Lam JUH, Rebolj M ( 2017 ) . Concordant testing results between various human papillomavirus assays in primary cervical cancer screening: systematic review . Clinical Microbiology and Infection vol. 24 , ( 1 ) 29 - 36 .
Lam JUH, Rebolj M, Ejegod DM, Pedersen H, Rygaard C, Lynge E, Thomsen LT, Kjaer SK et al. ( 2017 ) . Human papillomavirus self‐sampling for screening nonattenders: Opt‐in pilot implementation with electronic communication platforms . International Journal of Cancer vol. 140 , ( 10 ) 2212 - 2219 .
Rozemeijer K, Naber SK, Penning C, Overbeek LIH, Looman CWN, de Kok IMCM, Matthijsse SM, Rebolj M et al. ( 2017 ) . Cervical cancer incidence after normal cytological sample in routine screening using SurePath, ThinPrep, and conventional cytology: population based study . The BMJ vol. 356 ,
Ussi AE, Rebolj M, Thorat MA, Bietrix F, Fauvel A, Hajdúch M, Hill C, Walker I et al. ( 2016 ) . Assessing opportunities for coordinated R&D in early cancer detection and management in Europe . International Journal of Cancer vol. 140 , ( 7 ) 1700 - 1701 .
Rebolj M, Bonde J, Preisler S, Ejegod D, Rygaard C, Lynge E ( 2016 ) . Differential detection of Human Papillomavirus genotypes and cervical intraepithelial neoplasia by four commercial assays . Journal of Clinical MicrobiologyJCM.01321-16 - JCM.01321-16 .
Preisler S, Rebolj M, Ejegod DM, Lynge E, Rygaard C, Bonde J ( 2016 ) . Cross-reactivity profiles of hybrid capture II, cobas, and APTIMA human papillomavirus assays: split-sample study . BMC Cancer vol. 16 , ( 1 ) 510 - 510 .
Fornari D, Rebolj M, Bjerregård B, Lidang M, Christensen I, Høgdall E, Bonde J ( 2016 ) . Hybrid Capture 2 and cobas human papillomavirus assays perform similarly on SurePath samples from women with abnormalities . Cytopathology vol. 27 , ( 4 ) 249 - 260 .
Rebolj M, Bonde J, Preisler S, Ejegod D, Rygaard C, Lynge E ( 2016 ) . Human Papillomavirus Assays and Cytology in Primary Cervical Screening of Women Aged 30 Years and Above . PLOS ONE vol. 11 , ( 1 )
Rebolj M, Rask J, van Ballegooijen M, Kirschner B, Rozemeijer K, Bonde J, Rygaard C, Lynge E ( 2015 ) . Cervical histology after routine ThinPrep or SurePath liquid-based cytology and computer-assisted reading in Denmark . British Journal of Cancer vol. 113 , ( 9 ) 1259 - 1274 .
Rebolj M, Bonde J, Ejegod D, Preisler S, Rygaard C, Lynge E ( 2015 ) . A daunting challenge: Human Papillomavirus assays and cytology in primary cervical screening of women below age 30years . European Journal of Cancer vol. 51 , ( 11 ) 1456 - 1466 .
Ejegod DM, Rebolj M, Bonde J ( 2015 ) . Comparison of analytical and clinical performance of CLART HPV2 genotyping assay to Linear Array and Hybrid Capture 2: a split-sample study . BMC Cancer vol. 15 , ( 1 )
Lam JUH, Lynge E, Njor SH, Rebolj M ( 2015 ) . Hysterectomy and its impact on the calculated incidence of cervical cancer and screening coverage in Denmark . Acta Oncologica vol. 54 , ( 8 ) 1136 - 1143 .
Sander BB, Vázquez-Prada M, Rebolj M, Valentiner-Branth P, Lynge E ( 2015 ) . Mothers’ and their daughters’ use of preventive measures against cervical cancer . Scandinavian Journal of Public Health vol. 43 , ( 4 ) 415 - 422 .
Hammer T, Lynge E, Djurhuus GW, Joensen JE, Køtlum JE, Hansen SÓ, Sander BB, Mogensen O et al. ( 2014 ) . Cervical cancer screening in the Faroe Islands . Acta Oncologica vol. 54 , ( 2 ) 210 - 216 .
Frederiksen ME, Njor S, Lynge E, Rebolj M ( 2014 ) . Psychological effects of diagnosis and treatment of cervical intraepithelial neoplasia: a systematic review . Sexually Transmitted Infections vol. 91 , ( 4 )
Rebolj M, Lynge E, Ejegod D, Preisler S, Rygaard C, Bonde J ( 2014 ) . Comparison of three human papillomavirus DNA assays and one mRNA assay in women with abnormal cytology . Gynecologic Oncology vol. 135 , ( 3 ) 474 - 480 .
Dugué P, Rebolj M, Hallas J, Garred P, Lynge E ( 2014 ) . Risk of cervical cancer in women with autoimmune diseases, in relation with their use of immunosuppressants and screening: Population‐based cohort study . International Journal of Cancer vol. 136 , ( 6 ) e711 - e719 .
Dugué P-A, Lynge E, Rebolj M ( 2014 ) . Increased risk of high-grade squamous intraepithelial lesions in systemic lupus erythematosus: Additional data from Denmark . Autoimmunity Reviews vol. 13 , ( 12 ) 1241 - 1242 .
Bonde J, Rebolj M, Ejegod DM, Preisler S, Lynge E, Rygaard C ( 2014 ) . HPV prevalence and genotype distribution in a population-based split-sample study of well-screened women using CLART HPV2 Human Papillomavirus genotype microarray system . BMC Infectious Diseases vol. 14 , ( 1 )
Lynge E, Rygaard C, Baillet MV, Dugué P, Sander BB, Bonde J, Rebolj M ( 2014 ) . Cervical cancer screening at crossroads . Apmis vol. 122 , ( 8 ) 667 - 673 .
( 2014 ) . Outcomes in cervical screening using various cytology technologies . European Journal of Cancer Prevention vol. 23 , ( 2 ) 147 - 000 .
Sander BB, Rebolj M, Lynge E ( 2014 ) . Trends of cervical cancer in Greenland: A 60-year overview . Acta Oncologica vol. 53 , ( 4 ) 452 - 461 .
Lam JUH, Rebolj M, Dugué P-A, Bonde J, von Euler-Chelpin M, Lynge E ( 2014 ) . Condom use in prevention of Human Papillomavirus infections and cervical neoplasia: systematic review of longitudinal studies . Journal of Medical Screening vol. 21 , ( 1 ) 38 - 50 .
Rebolj M, Preisler S, Ejegod DM, Rygaard C, Lynge E, Bonde J ( 2014 ) . Disagreement between Human Papillomavirus Assays: An Unexpected Challenge for the Choice of an Assay in Primary Cervical Screening . PLOS ONE vol. 9 , ( 1 )
Rebolj M, Lynge E, Bonde J ( 2014 ) . Human papillomavirus testing and genotyping in cervical screening . Expert Review of Anticancer Therapy vol. 11 , ( 7 ) 1025 - 1033 .
Dugué P-A, Rebolj M, Garred P, Lynge E ( 2014 ) . Immunosuppression and risk of cervical cancer . Expert Review of Anticancer Therapy vol. 13 , ( 1 ) 29 - 42 .
Pedersen H, Ejegod DM, Rebolj M, Junge J, Franzmann M, Rygaard C, Bonde J ( 2014 ) . Comparison of Genomica CLART HPV2 genotyping assay to Roche Linear Array HPV genotyping assay and Qiagen Hybrid Capture 2 . APMIS . vol. 122 , 29 - 29 .
Rebolj M, Ejegod D, Preisler S, Rygaard C, Lynge E, Bonde J ( 2014 ) . Comparison of four HPV assays in a primary screening population on women ≥30 years of age . APMIS . vol. 122 , 6 - 6 .
Bonde J, Rebolj M, Preisler S, Ejegod D, Lynge E, Rygaard C ( 2014 ) . Detection of high-grade CIN by four HPV assays in women with abnormal cytology . APMIS . vol. 122 , 6 - 7 .
Preisler S, Rebolj M, Ejegod D, Lynge E, Rygaard C, Bonde J ( 2014 ) . HPV prevalence and genotype distribution in a population-based split-sample study of well-screened women using CLART HPV2 Human Papillomavirus genotype microarray system . APMIS . vol. 122 , 30 - 31 .
Ejegod DM, Rebolj M, Preisler S, Lynge E, Rygaard C, Bonde J ( 2014 ) . SurePath cytology medium for HPV testing using cobas HPV test, APTIMA HPV test, HC2, BD Onclarity HPV test and CLART HPV2 genotyping assay. A joint report form the Danish HORIZON study and the Danish BD Onclarity Trial . APMIS . vol. 122 , 31 - 32 .
Dugué P, Lynge E, Rebolj M ( 2013 ) . Mortality of non‐participants in cervical screening: Register‐based cohort study . International Journal of Cancer vol. 134 , ( 11 ) 2674 - 2682 .
Lynge E, Kragstrup J, Bjerrum L, Rebolj M ( 2013 ) . Incidence of Genital Warts in Young Danish Women . Clinical Infectious Diseases vol. 58 , ( 4 ) 601 - 602 .
Rask J, Lynge E, Franzmann M, Hansen B, Hjortebjerg A, Rygaard C, Schledermann D, Wåhlin A et al. ( 2013 ) . Impact of technology on cytology outcome in cervical cancer screening of young and older women . International Journal of Cancer vol. 134 , ( 9 ) 2168 - 2179 .
Dugué P-A, Rebolj M, Lynge E ( 2013 ) . Lead time and down-staging in the survival of cervical cancer cases detected by screening . Preventive Medicine vol. 57 , ( 4 )
Barken SS, Rebolj M, Lynge E, Junge J, Rygaard C ( 2013 ) . Outcomes in cervical screening using various cytology technologies . European Journal of Cancer Prevention vol. 22 , ( 4 ) 367 - 373 .
Rebolj M, Preisler S, Ejegod DM, Bonde J, Rygaard C, Lynge E ( 2013 ) . Prevalence of Human Papillomavirus Infection in Unselected SurePath Samples Using the APTIMA HPV mRNA Assay . Journal of Molecular Diagnostics vol. 15 , ( 5 ) 670 - 677 .
Preisler S, Rebolj M, Untermann A, Ejegod DM, Lynge E, Rygaard C, Bonde J ( 2013 ) . Prevalence of Human Papillomavirus in 5,072 Consecutive Cervical SurePath Samples Evaluated with the Roche Cobas HPV Real-Time PCR Assay . PLOS ONE vol. 8 , ( 3 )
Barken SS, Lynge E, Andersen ES, Rebolj M ( 2013 ) . Long‐term adherence to follow‐up after treatment of cervical intraepithelial neoplasia: nationwide population‐based study . Acta Obstetricia Et Gynecologica Scandinavica vol. 92 , ( 7 ) 852 - 857 .
( 2013 ) . Poster Sessions . Apmis . vol. 121 , 18 - 30 .
Goldman B, Rebolj M, Rygaard C, Preisler S, Ejegod DM, Lynge E, Bonde J ( 2013 ) . Patterns of cervical coinfection with multiple human papilloma virus types in a screening population in Denmark . Vaccine vol. 31 , ( 12 ) 1604 - 1609 .
Rebolj M, Preisler S, Ejegod DM, Bonde J, Rygaard C, Lynge E ( 2013 ) . APTIMA HPV assay testing on the PANTHER platform using SurePath samples . APMIS . vol. 121 , 19 - 19 .
Ejegod DM, Preisler S, Rebolj M, Untermann A, Lynge E, Rygaard C, Bonde J ( 2013 ) . Cross reactivity of Roche cobas® HPV test, Qiagen Hybrid Capture 2®, and Gen-Probe APTIMA® with non-oncogenic human papillomavirus types; Implications for molecular cervical cancer . APMIS . vol. 121 , 2 - 2 .
Rebolj M, Preisler S, Ejegod DM, Untermann A, Rygaard C, Lynge E, Bonde J ( 2013 ) . Disagreement between Human Papillomavirus assays in primary cervical screening: Hybrid Capture 2, cobas, CLART, and APTIMA . APMIS . vol. 121 , 3 - 3 .
Ejegod DM, Rebolj M, Preisler S, Lynge E, Rygaard C, Bonde J ( 2013 ) . Experiences with molecular HPV testing using APTIMA, CLART, and cobas HPV test in SurePath liquid based cytology samples . APMIS . vol. 121 , 18 - 19 .
Bonde J, Rebolj M, Preisler S, Ejegod DM, Lynge E, Rygaard C ( 2013 ) . Genotype-specific prevalence of HPV infection in Denmark . APMIS . vol. 121 , 20 - 20 .
Ejegod DM, Preisler S, Rebolj M, Untermann A, Lynge E, Rygaard C, Bonde J ( 2013 ) . Reproducibility of Human Papillomavirus detection using the Roche cobas HPV Test, QIAGEN Hybrid Capture 2, Gen-Probe APTIMA, and Genomica CLART assays; Implications for molecular cervical screening . APMIS . vol. 121 , 18 - 18 .
Rebolj M, Pribac I, Frederiksen ME, Lynge E ( 2013 ) . The problem of false-positive human papillomavirus DNA tests in cervical screening . Current Pharmaceutical Design vol. 19 , ( 8 ) 1439 - 1449 .
Lynge E, Rygaard C, Rebolj M ( 2012 ) . Prøv et offentligt/privat forskningssamarbejde . Ugeskrift for Laeger vol. 174 , ( 44 ) 2731 - 2731 .
Rebolj M, Helmerhorst T, Habbema D, Looman C, Boer R, van Rosmalen J, van Ballegooijen M ( 2012 ) . Risk of cervical cancer after completed post-treatment follow-up of cervical intraepithelial neoplasia: population based cohort study . The BMJ vol. 345 , ( oct31 4 )
Frederiksen ME, Lynge E, Rebolj M ( 2012 ) . Women's preferences regarding options for management of atypical, borderline and low‐grade cervical abnormalities . Cytopathology vol. 23 , ( 3 ) 201 - 201 .
Dugué P-A, Lynge E, Bjerregaard B, Rebolj M ( 2012 ) . Non-participation in screening: The case of cervical cancer in Denmark . Preventive Medicine vol. 54 , ( 3-4 ) 266 - 269 .
Untermann A, Preisler S, Rebolj M, Ejegod D M, Junge J, Lynge E, Rygaard C, Bonde J ( 2012 ) . Choice of HPV detection system determines the percentage of women who can be checked-out of the cervical screening programme implementing the new "≥60 year's check-out" guideline . APMIS . vol. 120 , 4 - 4 .
Ejegod DM, Preisler S, Rebolj M, Untermann A, Lynge E, Rygaard C, Bonde J ( 2012 ) . Cross reactivity of Roche cobas®HPV test, Qiagen Hybrid Capture 2, and Gen-Probe APTIMA with non-oncogenic human papillomavirus types. Implications for molecular cervical cancer screening . APMIS . vol. 120 , 26 - 27 .
Barken SS, Rebolj M, Lynge E, Junge J, Rygaard C ( 2012 ) . Cytological outcomes in cervical screening after implementation of new technology: What has age got to do with it? . APMIS . vol. 120 , 26 - 26 .
Sander B, Rebolj M, Lynge E ( 2012 ) . Historical Trends of Cervical Cancer in Greenland: A 60-Year Overview . ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA . vol. 91 , 125 - 125 .
Sander B, Rebolj M, Valentiner-Branth P, Lynge E ( 2012 ) . Introduction of Human Papillomavirus Vaccination in Nordic Countries . ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA . vol. 91 , 124 - 125 .
Preisler S, Rebolj M, Untermann A, Ejegod DM, Lynge E, Rygaard C, Bonde J ( 2012 ) . Population based prevalence of human papillomavirus in > 5000 unselected, consecutive cervical SurePath® samples evaluated by Roche cobas®HPV real-time PCR, Qiagen Hybrid Capture 2®, Gen-Probe APTIMA® and Genomica CLART® assays: Implications for molecular cervical cancer screening . APMIS . vol. 120 , 23 - 24 .
Preisler S, Rebolj M, Untermann A, Ejegod MD, Lynge E, Rygaard C, Bonde J ( 2012 ) . Reproducibility of human papillomavirus detection using the Roche cobas®4800 real-time PCR, Hybrid Capture 2, Gen-Probe APTIMA and Genomica CLART assays. Implications for molecular cervical cancer screening . APMIS . vol. 120 , 27 - 27 .
Rebolj M, Njor SH, Lynge E ( 2012 ) . Restriction of human papillomavirus DNA testing in primary cervical screening to women above age 30 . European Journal of Cancer Prevention vol. 21 , ( 1 ) 73 - 81 .
Sander BB, Rebolj M, Valentiner-Branth P, Lynge E ( 2011 ) . Introduction of human papillomavirus vaccination in Nordic countries . Vaccine vol. 30 , ( 8 ) 1425 - 1433 .
Frederiksen M, Lynge E, Rebolj M ( 2011 ) . What women want. Women’s preferences for the management of low‐grade abnormal cervical screening tests: a systematic review . BJOG An International Journal of Obstetrics & Gynaecology vol. 119 , ( 1 ) 7 - 19 .
Barken SS, Rebolj M, Andersen ES, Lynge E ( 2011 ) . Frequency of cervical intraepithelial neoplasia treatment in a well‐screened population . International Journal of Cancer vol. 130 , ( 10 ) 2438 - 2444 .
Von Euler-Chelpin M, Lynge E, Rebolj M ( 2011 ) . Register-based studies of cancer screening effects . Scandinavian Journal of Public Health vol. 39 , ( 7_suppl ) 158 - 164 .
Lynge E, Sandegaard JL, Rebolj M ( 2011 ) . The Danish National Patient Register . Scandinavian Journal of Public Health vol. 39 , ( 7_suppl ) 30 - 33 .
Rebolj M, Bonde J, Njor SH, Lynge E ( 2011 ) . Human papillomavirus testing in primary cervical screening and the cut-off level for hybrid capture 2 tests: systematic review . The BMJ vol. 342 , ( may23 1 )
Briët MC, Berger THD, van Ballegooijen M, Boon ME, Rebolj M ( 2011 ) . Effects of Streamlining Cervical Cancer Screening the Dutch Way . Acta Cytologica vol. 54 , ( 6 ) 1095 - 1100 .
Rebolj M, Pribac I, Lynge E ( 2011 ) . False-positive Human Papillomavirus DNA tests in cervical screening: It is all in a definition . European Journal of Cancer vol. 47 , ( 2 ) 255 - 261 .
Rebolj M, Bonde J, Njor S, Lynge E ( 2011 ) . Human papillomavirus testing in primary cervical screening and the cut-off for hybrid capture 2 tests . APMIS . vol. 119 , 23 - 23 .
Untermann A, Asmussen L, Brink HM, Rebolj M, Lynge E, Rygaard C, Bonde J ( 2011 ) . Reproducibility of human papilloma virus detection using the Roche COBAS 4800 real-time PCR platform: Implications for molecular cervical cancer screening . APMIS . vol. 119 , 18 - 18 .
Rebolj M, Lynge E ( 2010 ) . Incomplete follow-up of positive HPV tests: overview of randomised controlled trials on primary cervical screening . British Journal of Cancer vol. 103 , ( 3 ) 310 - 314 .
Lynge E, Rebolj M ( 2010 ) . Re: Age-Specific Evaluation of Primary Human Papillomavirus Screening vs Conventional Cytology in a Randomized Setting . Journal of the National Cancer Institute vol. 102 , ( 10 ) 739 - 739 .
Rebolj M, Lynge E ( 2010 ) . Has Cytology Become Obsolete as a Primary Test in Screening for Cervical Cancer? . Journal of Medical Screening vol. 17 , ( 1 ) 1 - 2 .
Rebolj M, Bjerregaard B, Rygaard C, Clausen LB, Lynge E ( 2010 ) . FREQUENCY OF MEDICAL PROCEDURES IN CYTOLOGY-BASED CERVICAL SCREENING: DANISH EXPERIENCE . ACTA CYTOLOGICA . vol. 54 , 398 - 399 .
Lynge E, Rebolj M ( 2009 ) . Primary HPV screening for cervical cancer prevention: results from European trials . Nature Reviews Clinical Oncology vol. 6 , ( 12 ) 699 - 706 .
Ronco G, van Ballegooijen M, Becker N, Chil A, Fender M, Giubilato P, Kurtinaitis J, Lancucki L et al. ( 2009 ) . Process performance of cervical screening programmes in Europe . European Journal of Cancer vol. 45 , ( 15 ) 2659 - 2670 .
Anttila A, von Karsa L, Aasmaa A, Fender M, Patnick J, Rebolj M, Nicula F, Vass L et al. ( 2009 ) . Cervical cancer screening policies and coverage in Europe . European Journal of Cancer vol. 45 , ( 15 ) 2649 - 2658 .
Arbyn M, Rebolj M, De Kok IMCM, Fender M, Becker N, O’Reilly M, Andrae B ( 2009 ) . The challenges of organising cervical screening programmes in the 15 old member states of the European Union . European Journal of Cancer vol. 45 , ( 15 ) 2671 - 2678 .
Rebolj M, Van Ballegooijen M, Lynge E, Looman C, Essink-Bot ML, Boer R, Habbema D ( 2009 ) . Incidence of cervical cancer after several negative smear results by age 50: Prospective observational study . BMJ (Online) vol. 338 , ( 7702 ) 1058 - 1060 .
Rebolj M, van Ballegooijen M, Lynge E, Looman C, Essink-Bot M-L, Boer R, Habbema D ( 2009 ) . Incidence of cervical cancer after several negative smear results by age 50: prospective observational study . The BMJ vol. 338 , ( apr24 1 )
de Kok IMCM, Polder JJ, Habbema JDF, Berkers L-M, Meerding WJ, Rebolj M, van Ballegooijen M ( 2009 ) . The impact of healthcare costs in the last year of life and in all life years gained on the cost-effectiveness of cancer screening . British Journal of Cancer vol. 100 , ( 8 ) 1240 - 1244 .
Othman NH, Rebolj M ( 2009 ) . Challenges to cervical screening in a developing country: The case of Malaysia . Asian Pacific Journal of Cancer Prevention vol. 10 , ( 5 ) 747 - 752 .
Bais AG, Eijkemans MJC, Rebolj M, Snijders PJF, Verheijen RHM, van Ballegooijen M, Meijer CJLM, Helmerhorst TJM ( 2008 ) . Post‐treatment CIN: Randomised clinical trial using hrHPV testing for prediction of residual/recurrent disease . International Journal of Cancer vol. 124 , ( 4 ) 889 - 895 .
Dillner J, Rebolj M, Birembaut P, Petry K-U, Szarewski A, Munk C, de Sanjose S, Naucler P et al. ( 2008 ) . Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study . The BMJ vol. 337 , ( oct13 1 )
Lourenco T, Pickard R, Vale L, Grant A, Fraser C, MacLennan G, N’Dow J ( 2008 ) . Minimally invasive treatments for benign prostatic enlargement: systematic review of randomised controlled trials . The BMJ vol. 337 , ( oct09 2 )
Rebolj M, van Ballegooijen M, van Kemenade F, Looman C, Boer R, Habbema JDF ( 2008 ) . No increased risk for cervical cancer after a broader definition of a negative Pap smear . International Journal of Cancer vol. 123 , ( 11 ) 2632 - 2635 .
Rebolj M, Bais AG, van Ballegooijen M, Boer R, Meerding W, Helmerhorst TJM, Habbema JDF ( 2007 ) . Human papillomavirus triage of women with persistent borderline or mildly dyskaryotic smears: Comparison of costs and side effects of three alternative strategies . International Journal of Cancer vol. 121 , ( 7 ) 1529 - 1535 .
Berkers LM, van Ballegooijen M, van Kemenade FJ, Rebolj M, Essink-Bot ML, Helmerhorst TJM, Habbema JDF ( 2007 ) . The 1996 revision of the Dutch cervical cancer screening programme: increased coverage, fewer repeat smears and less opportunistic screening . Nederlands Tijdschrift voor Geneeskunde vol. 151 , ( 23 ) 1288 - 1294 .
Rebolj M, van Ballegooijen M, Essink-Bot L, Boer R, Habbema D ( 2007 ) . Incidence of cervical cancer in women around age 50 with a history of 3 or more negative smears . ACTA CYTOLOGICA . vol. 51 , 289 - 289 .
Rebolj M, van Ballegooijen M, Essink-Bot L, Boer R, Habbema D ( 2007 ) . No excess cancer incidence in women with a negative triage after borderline or mildly dyskaryotic smears . ACTA CYTOLOGICA . vol. 51 , 358 - 358 .
Rebolj M, van Ballegooijen M, Essink-Bot M, Boer R, Habbema D ( 2007 ) . No increase in incidence of interval cancers in the Netherlands after implementation of a less restrictive definition of a negative pap smear . ACTA CYTOLOGICA . vol. 51 , 357 - 358 .
Rebolj M, van Ballegooijen M, Essink-Bot L, Boer R, Habbema D ( 2007 ) . Women with cervical intraepithelial neoplasia at increased risk for invasive cervical cancer after completing recommended follow-up . ACTA CYTOLOGICA . vol. 51 , 290 - 290 .
Rebolj M, van Ballegooijen M, Berkers L, Habbema D ( 2006 ) . Monitoring a national cancer prevention program: Successful changes in cervical cancer screening in the netherlands . International Journal of Cancer vol. 120 , ( 4 ) 806 - 812 .
Bos AB, Rebolj M, Habbema JDF, van Ballegooijen M ( 2006 ) . Nonattendance is still the main limitation for the effectiveness of screening for cervical cancer in the Netherlands . International Journal of Cancer vol. 119 , ( 10 ) 2372 - 2375 .
Rebolj M, Van Ballegooijen M, Berkers LM, Habbema JDF ( 2006 ) . Monitoring a cancer prevention program: Successful changes in cervical cancer screening in the Netherlands . EUROPEAN JOURNAL OF EPIDEMIOLOGY . vol. 21 , 77 - 77 .
Bais AG, Rebolj M, Snijders PJF, de Schipper FA, van der Meulen DAJ, Verheijen RHM, Voorhorst F, van Ballegooijen M et al. ( 2005 ) . Triage using HPV‐testing in persistent borderline and mildly dyskaryotic smears: Proposal for new guidelines . International Journal of Cancer vol. 116 , ( 1 ) 122 - 129 .
Back to Search